Home » Newsletters » BioWorld Science

BioWorld Science

July 1, 2010

View Archived Issues

PET/CT tracer anti-3-[18F]-FACBC effectively detects recurrent prostate cancer

Integrin alpha-V/beta-6 shows potential as biomarker for pancreatic cancer

Dexrazoxane is cardioprotective in rat model of myocardial infarction

Solvay discloses new potassium channel blockers

GlaxoSmithKline presents new AMPA receptor agonists

Centocor Ortho Biotech and Medivir claim new NS5B polymerase inhibitors

TopoTarget presents novel Nampt inhibitors

Novel P2X3 and P2X2/3 receptor antagonists claimed by Roche

TAK-701 shows promise in nonhematologic tumors

TXA-127 obtains FDA orphan drug status to enhance stem cell engraftment

Futura Medical and GSK join to develop TPR-100 for topical pain relief

Acotiamide meets primary endpoints in phase III trial in functional dyspepsia

FDA grants orphan drug status to Octreolin for oral treatment of acromegaly

AMAG and Takeda begin global registrational program of ferumoxytol

TZP-102 improves diabetic gastroparesis-related symptoms in phase II trial

Posaconazole for Chagas' disease enters phase II trial in South America

Vitae receives milestone payment as 11-beta-HSD1 inhibitor advances to phase I

EMA issues encouraging scientific advice on phase III perifosine trial in colorectal cancer

Tolerx begins confirmatory phase III trial of otelixizumab in type 1 diabetes

Pluristem to design phase IIb trials of PLX-PAD in CLI and claudication

Cubist meets objectives in phase II CXA-101 urinary tract infection study

Alnylam obtains approval to initiate phase I ALN-TTR01 study in amyloidosis

Alimera submits Iluvien NDA to FDA for diabetic macular edema

Immunovaccine and Oncothyreon to jointly develop cancer vaccine

Single-molecule digital ELISA shows potential in diagnosing prostate cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...